All In Biotech

Drug Trial Radar · NCT07951606

Safty and Efficacy of KH658 in Subjects With Diabetic Retinopathy

A Phase II Study to Evaluate the Safty and Efficacy of KH658 Gene Therapy in Participants With Diabetic Retinopathy (DR)

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Feb 2027

Primary completion

Jun 2028

Study completion Jun 2032

Sponsor

Sponsor type
Industry
First posted
Nov 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

KH658 is a adeno-associated virus (AAV) vector-based gene therapy for suprachoroidal space injection. The long-term, stable therapeutic protein after one time injection for DR could potentially reduce the treatment burden and maintain visual acuity and retinal anatomical stability

Conditions

  • Diabetic Retinopathy

Interventions

  • KH658 Dose 1Genetic

    KH658 Dose 1 suprachoriodal single injection

  • KH658 Dose 2Genetic

    KH658 Dose 2 suprachoriodal single injection

  • RanibizumabDrug

    Administered by intravitreal injection once a month

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants with a ≥2 steps DRSS Improvement From Baseline in Diabetic RetinopthyTime frame: At Week 52
  2. Proportion of Participants Developing Vision-Threatening Events (VTEs)Time frame: At Week 52

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.